# APLM earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/APLM) · [Earnings tab](https://www.lopjlb.com/stock/APLM?tab=earnings) Updated: 2026-09-24T08:10:14 Quarters analyzed: 1 ## Cross-quarter narrative Apollomics’ FY2023 earnings call highlighted that the company is maintaining its cash runway of $37.8 million through Q1 2025 while concentrating resources on two lead programs, vebreltinib and APL‑106. Management reported progress on the global SPARTA trial for vebreltinib and confirmed conditional approval in China, as well as completed enrollment for the Phase‑3 bridging study of APL‑106 in China. The firm also noted ongoing work on a Glycomimetics AML phase‑3 read‑out and pre‑clinical data slated for AACR 2024, while preparing an NDA for vebreltinib in a MET‑amplification indication. FDA feedback indicated a need for additional patient enrollment, creating regulatory timeline uncertainty and a possible extension of the 12‑month follow‑up that could shift the NDA filing to 2026. The cost base is rising due to trial spend, and the limited cash runway adds pressure to fund extended studies. Overall, the call conveyed moderate visibility on regulatory milestones, a stable focus on the two lead candidates, and heightened awareness of enrollment, cash‑runway, and competitive risks. ## Latest CallCard · Q4 Apollomics reported FY2023 results, highlighted progress on vebreltinib and APL‑106, discussed FDA feedback requiring more patient enrollment, and said its $37.8M cash will fund operations through Q1 2025 while focusing on two lead candidates. **Guidance:** maintained — Management indicated cash runway sufficient through Q1 2025, no change to prior guidance **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks emphasized significant accomplishments and advancing trials, indicating optimism ### Demand visibility Moderate visibility on regulatory timelines FDA feedback requires additional patient enrollment, extending 12‑month follow‑up to summer 2025 and possibly pushing NDA submission to 2026 ### Margins / costs Rising cost base driven by clinical trial spend R&D expenses $34.2M in 2023, G&A $20.6M, both up year‑over‑year due to trial enrollment and public‑company costs ### Capital allocation Capital focused on two lead programs and cash runway Cash $37.8M intended to fund trial enrollment, FDA interactions and operating expenses through Q1 2025 ### Milestones - **Global SPARTA trial for vebreltinib** [on_track]: >500 patients treated across 90 sites, interim data encouraging - **Conditional approval in China for vebreltinib (Nov 2023)** [delivered]: Everstone holds exclusive rights in Greater China - **Phase‑3 bridging study enrollment for APL‑106 in China** [delivered]: Enrollment completed end of 2023 - **Top‑line results from Glycomimetics AML phase‑3 study** [on_track]: Expected Q2 2024 - **Pre‑clinical data presentation at AACR 2024** [on_track]: Planned posters on vebreltinib - **NDA submission for vebreltinib MET‑amplification indication** [new]: Targeted 2026 pending additional enrollment - **Continued enrollment in Sparta cohorts** [at_risk]: May extend into 2025 affecting timeline - **Cash runway guidance through Q1 2025** [on_track]: Cash $37.8M expected to fund operations ### Fears / risks - **Regulatory**: FDA requires more patient data before NDA acceptance, creating timeline uncertainty - **Enrollment**: Need to enroll additional patients in Sparta cohorts, risking delays - **Cash/runway**: Cash sufficient only through Q1 2025, limiting ability to fund extended trials - **Competitive**: Reliance on two lead candidates may be risky if competitors advance faster - **Operational**: Execution of multi‑regional trials adds complexity and potential delays ### Key quotes > “2023 was a year of significant accomplishment as we made substantial progress in our two lead drug candidates, vebreltinib and ophthalescelen” > “The objective response rate was 66.2%, supported by median duration of response of 16.5 months” > “the 12 months follow up time will coming up in the summer, but if we need additional patient to be enrolled, that will basically extend another 12 months” > “As of December 31, 2023, cash, cash equivalents, bank deposits and money market funds were $37.8 million, as compared to $58.9 million as of December 31, 2022” > “we said we've got cash through the first quarter of 2025. So five quarters there” ## Quarter one-liners - **2023 Q4:** Apollomics reported FY2023 results, highlighted progress on vebreltinib and APL‑106, discussed FDA feedback requiring more patient enrollment, and said its $37.8M cash will fund operations through Q1 2025 while focusing on two lead candidates. ## Theme arcs - **Regulatory timeline uncertainty** (new): FDA requires more patient data, pushing potential NDA to 2026 - **Cash runway limitation** (new): Cash sufficient only through Q1 2025, constraining extended trial funding - **Trial enrollment risk** (new): Additional patient enrollment needed for SPARTA and other studies - **Rising cost base** (new): Clinical trial spend driving higher expenses - **Focus on two lead candidates** (stable): Continued concentration on vebreltinib and APL‑106 ## Fear persistence - **Regulatory** [new]: FDA demands more patient data, creating timeline risk - **Enrollment** [new]: Need for extra patients could delay milestones - **Cash/runway** [new]: Cash only covers operations to Q1 2025 - **Competitive** [new]: Reliance on two candidates risky if rivals advance faster - **Operational** [new]: Multi‑regional trial execution adds complexity ## Guidance path 2023 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/APLM`